At Shockwave, we’re committed to the creation of sound clinical evidence to support the adoption and long-term utilization of our technology. This includes a balance of high-quality Shockwave-sponsored and investigator-initiated research studies to advance the knowledge of our technology’s performance in daily practice.
Shockwave's Clinical Evidence Pillars
What We Set Out to Demonstrate
Consistent safety profile across studies for the patient and within the vessel
Highly effective in dilating calcified lesions – from the simple to the complex
Economic value through the reduction of complications and cost escalation
Ease of Use
Seamless integration with consistent outcomes and minimal learning curve
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.
IT’S TIME TO
COUNTDOWN TO CAD III PRESENTATION
Caution: Investigational device. Limited by Federal (U.S.) law to investigational use.